Following safety concerns, two clinical trials evaluating palovarotene for the treatment of rare bone disorders have been placed on partial hold (for children). As the drug was expected to fill the revenue hole which is likely to be created with the entry of generics for Somatuline, the news was not taken well by the markets. Given the uncertainty, Ipsen could remain under pressure in the near term, however, it appears as an attractive investment proposition for the mid-term.
11 Dec 2019
Partial hold on rare bone disorder studies
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Partial hold on rare bone disorder studies
Ipsen SA (IPN:WBO) | 0 0 5.0% | Mkt Cap: 10,144m
- Published:
11 Dec 2019 -
Author:
Sumit Sayal -
Pages:
2
Following safety concerns, two clinical trials evaluating palovarotene for the treatment of rare bone disorders have been placed on partial hold (for children). As the drug was expected to fill the revenue hole which is likely to be created with the entry of generics for Somatuline, the news was not taken well by the markets. Given the uncertainty, Ipsen could remain under pressure in the near term, however, it appears as an attractive investment proposition for the mid-term.